High concentration anti-C5 antibody formulations
US11365241B2 · kind B2 · utility
2Cited by
52References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 27, 2018 |
| Grant date | Jun 21, 2022 |
| Priority date | — |
| Expiry date | Oct 22, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to stable aqueous solutions comprising a high concentration of an anti-C5 antibody (e.g., ravulizumab) and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), using the solutions. Also featured were therapeutic kits containing one or more of the solutions and a means for administering the solutions to a patient in need such a treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.